Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NETosis in the pathogenesis of acute lung injury following cutaneous chemical burns
Ranu Surolia, Fu Jun Li, Zheng Wang, Mahendra Kashyap, Ritesh Kumar Srivastava, Amie M. Traylor, Pooja Singh, Kevin G. Dsouza, Harrison Kim, Jean-Francois Pittet, Jaroslaw W. Zmijewski, Anupam Agarwal, Mohammad Athar, Aftab Ahmad, Veena B. Antony
Ranu Surolia, Fu Jun Li, Zheng Wang, Mahendra Kashyap, Ritesh Kumar Srivastava, Amie M. Traylor, Pooja Singh, Kevin G. Dsouza, Harrison Kim, Jean-Francois Pittet, Jaroslaw W. Zmijewski, Anupam Agarwal, Mohammad Athar, Aftab Ahmad, Veena B. Antony
View: Text | PDF
Research Article Pulmonology

NETosis in the pathogenesis of acute lung injury following cutaneous chemical burns

  • Text
  • PDF
Abstract

Despite the high morbidity and mortality among patients with extensive cutaneous burns in the intensive care unit due to the development of acute respiratory distress syndrome, effective therapeutics remain to be determined. This is primarily because the mechanisms leading to acute lung injury (ALI) in these patients remain unknown. We test the hypothesis that cutaneous chemical burns promote lung injury due to systemic activation of neutrophils, in particular, toxicity mediated by the deployment of neutrophil extracellular traps (NETs). We also demonstrate the potential benefit of a peptidyl arginine deiminase 4 (PAD4) inhibitor to prevent NETosis and to preserve microvascular endothelial barrier function, thus reducing the severity of ALI in mice. Our data demonstrated that phenylarsine oxide (PAO) treatment of neutrophils caused increased intracellular Ca2+-associated PAD4 activity. A dermal chemical burn by lewisite or PAO resulted in PAD4 activation, NETosis, and ALI. NETs disrupted the barrier function of endothelial cells in human lung microvascular endothelial cell spheroids. Citrullinated histone 3 alone caused ALI in mice. Pharmacologic or genetic abrogation of PAD4 inhibited lung injury following cutaneous chemical burns. Cutaneous burns by lewisite and PAO caused ALI by PAD4-mediated NETosis. PAD4 inhibitors may have potential as countermeasures to suppress detrimental lung injury after chemical burns.

Authors

Ranu Surolia, Fu Jun Li, Zheng Wang, Mahendra Kashyap, Ritesh Kumar Srivastava, Amie M. Traylor, Pooja Singh, Kevin G. Dsouza, Harrison Kim, Jean-Francois Pittet, Jaroslaw W. Zmijewski, Anupam Agarwal, Mohammad Athar, Aftab Ahmad, Veena B. Antony

×

Figure 6

PAO-induced NETs disrupt barrier function in HLMVEC monolayers and spheroids.

Options: View larger image (or click on image) Download as PowerPoint
PAO-induced NETs disrupt barrier function in HLMVEC monolayers and spher...
(A) Representative immunoblot of ZO-1, VE-cadherin, and β-catenin after treatment with NETs isolated from human neutrophils after PAO treatment for indicated time points (n = 5). (B) Comparisons of normalized resistance of the HLMVEC monolayer upon stimulation with NETs. Each line represents NETs from an individual human subject. The stimulation time point is set as t = 0. (C) FITC-Dextran 4000 permeability assay. HLMVEC monolayers treated with vehicle (control), NETs, NE antibody, NE antibody and NETs, Cit-H3 antibody, Cit-H3 antibody and NETs, and Cit-H3 antibody, NE antibody, and NETs for 24 hours. (D) Representative data for comparisons of normalized resistance upon stimulation with NETs derived from controls (untreated), PAO, GSK484, and GSK484- and PAO-cotreated neutrophils in HLMVEC monolayers (n = 3 subjects). (E) Measurements of extracellular dsDNA levels in the supernatant of the control, PAO, GSK484, and GSK484- and PAO-cotreated neutrophils (n = 4). (F) Phase contrast images of spheroids treated with PAO or NETs (n = 3). Original magnification (lower panel), ×75. Images (G) and graph (H) for dextran permeability assay in primary HLMVEC spheroids. Scale bar: 200 μm. (I) Fluorescence images showing the expression of tight junction markers, ZO-1 (green), and extracellular dsDNA (NETs) (TOTO 3, red). Nuclei of spheroids were stained with Hoechst dye (blue). Scale bar: 100 μm. Inset showing magnified fluorescence image showing ZO-1 expression. Original magnification, ×15,000. (J) Dextran permeability assay in primary HLMVECs. All data are shown as the mean ± SEM. *P < 0.05. Statistics: 1-way ANOVA followed by Tukey’s multiple comparisons test (C and E) and Wilcoxon’s test (H and J).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts